Lounici A, Iacob A, Hongler K, Molling M, Drechsler M, Hersberger L
Nutrients. 2025; 17(1.
PMID: 39796465
PMC: 11723184.
DOI: 10.3390/nu17010031.
Watanangura A, Meller S, Farhat N, Suchodolski J, Pilla R, Khattab M
Front Vet Sci. 2024; 11:1385469.
PMID: 38978633
PMC: 11229054.
DOI: 10.3389/fvets.2024.1385469.
Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G
Curr Addict Rep. 2024; 9(4):660-670.
PMID: 38362235
PMC: 10868722.
DOI: 10.1007/s40429-022-00446-3.
Lochner C, Naude P, Stein D
Curr Neuropharmacol. 2023; 22(5):963-975.
PMID: 37644747
PMC: 10845092.
DOI: 10.2174/1570159X21666230829145425.
Bendriss G, MacDonald R, McVeigh C
Int J Mol Sci. 2023; 24(15).
PMID: 37569349
PMC: 10419219.
DOI: 10.3390/ijms241511978.
Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls.
Biria M, Banca P, Healy M, Keser E, Sawiak S, Rodgers C
Nat Commun. 2023; 14(1):3324.
PMID: 37369695
PMC: 10300066.
DOI: 10.1038/s41467-023-38695-z.
Untargeted metabolomics analysis in drug-naïve patients with severe obsessive-compulsive disorder.
Li Z, Gao J, Lin L, Zheng Z, Yan S, Wang W
Front Neurosci. 2023; 17:1148971.
PMID: 37332872
PMC: 10272357.
DOI: 10.3389/fnins.2023.1148971.
Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.
Ferguson A, Khan A, Abuzainah B, Chaudhuri D, Khan K, Al Shouli R
Cureus. 2023; 15(4):e37833.
PMID: 37213965
PMC: 10198239.
DOI: 10.7759/cureus.37833.
Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial.
Maraone A, Trebbastoni A, Di Vita A, DAntonio F, de Lena C, Pasquini M
JMIR Res Protoc. 2023; 12:e39223.
PMID: 37166948
PMC: 10214117.
DOI: 10.2196/39223.
Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction.
Jalal B, Chamberlain S, Sahakian B
Brain Behav. 2023; 13(6):e3000.
PMID: 37137502
PMC: 10275553.
DOI: 10.1002/brb3.3000.
Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson's Disease.
Epping-Jordan M, Girard F, Bessis A, Mutel V, Bolea C, Derouet F
Cells. 2023; 12(7).
PMID: 37048075
PMC: 10093229.
DOI: 10.3390/cells12071004.
Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia.
Morgenroth C, Kleymann P, Ripke S, Awasthi S, Wagner E, Oviedo-Salcedo T
Eur Arch Psychiatry Clin Neurosci. 2023; 274(1):181-193.
PMID: 37020043
PMC: 10786740.
DOI: 10.1007/s00406-023-01593-y.
Obsessive-Compulsive Disorder, PANDAS, and Tourette Syndrome: Immuno-inflammatory Disorders.
Marazziti D, Palermo S, Arone A, Massa L, Parra E, Simoncini M
Adv Exp Med Biol. 2023; 1411:275-300.
PMID: 36949315
DOI: 10.1007/978-981-19-7376-5_13.
Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients.
Swierkosz-Lenart K, Dos Santos J, Elowe J, Clair A, Bally J, Riquier F
Front Psychiatry. 2023; 14:1065812.
PMID: 36873207
PMC: 9978117.
DOI: 10.3389/fpsyt.2023.1065812.
Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-traumatic brain injury anxiety and social impairment.
Frank D, Gruenbaum B, Shelef I, Zvenigorodsky V, Severynovska O, Fleidervish I
Transl Psychiatry. 2023; 13(1):41.
PMID: 36739271
PMC: 9899234.
DOI: 10.1038/s41398-023-02329-1.
Neurogenetics of Dynamic Connectivity Patterns Associated With Obsessive-Compulsive Symptoms in Healthy Children.
Sunol M, Alemany S, Bustamante M, Diez I, Contreras-Rodriguez O, Laudo B
Biol Psychiatry Glob Open Sci. 2022; 2(4):411-420.
PMID: 36324658
PMC: 9616269.
DOI: 10.1016/j.bpsgos.2021.11.009.
The Potential of -Acetylcysteine for Treatment of Trichotillomania, Excoriation Disorder, Onychophagia, and Onychotillomania: An Updated Literature Review.
Lee D, Lipner S
Int J Environ Res Public Health. 2022; 19(11).
PMID: 35681955
PMC: 9180086.
DOI: 10.3390/ijerph19116370.
Glucose metabolism and AD: evidence for a potential diabetes type 3.
Gonzalez A, Calfio C, Churruca M, Maccioni R
Alzheimers Res Ther. 2022; 14(1):56.
PMID: 35443732
PMC: 9022265.
DOI: 10.1186/s13195-022-00996-8.
WNT/β-catenin pathway and circadian rhythms in obsessive-compulsive disorder.
Vallee A, Lecarpentier Y, Vallee J
Neural Regen Res. 2022; 17(10):2126-2130.
PMID: 35259818
PMC: 9083179.
DOI: 10.4103/1673-5374.332133.
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.
Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M
BMC Pharmacol Toxicol. 2021; 22(1):69.
PMID: 34736541
PMC: 8569963.
DOI: 10.1186/s40360-021-00534-6.